

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Søren Mouritsen et al.)	Group Art Unit: 1644
)	
Application No.: 08/955,373)	Examiner: SCHWADRON, Ronald B.
)	
Filed: October 21, 1997)	Confirmation No.: 7254
)	
For: INDUCING ANTIBODY)	
RESPONSE AGAINST SELF-)	
PROTEINS WITH THE AID OF)	
FOREIGN T-CELL EPITOPES)	

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute “prior art.” If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited document(s) do not constitute “prior art” under United States law, Applicants reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there are any additional fees due in connection with the filing of this Statement, please charge the fee to **Deposit Account 50-5338**, referencing **Docket No. BNIT0003-PCT-US**. The Commissioner is not authorized to charge the Issue Fee to the Deposit Account.

Respectfully submitted,

Dated: June 17, 2011

By: /David C. Hoffman/
David C. Hoffman, Ph.D., J.D.
Reg. No. 59,821
BN ImmunoTherapeutics, Inc.
2425 Garcia Avenue
Mountain View, CA 94043-1106
Phone: (650) 681-4780
E-mail: David.Hoffman@bn-it.com